On August 10, 2023, Inversago Pharma announced its business combination with Nova Nordisk for US$1.075 billion pursuant to the completion of certain development and commercial milestones. This acquisition will strengthen Nova Nordisk’s clinical development and research capability for obesity and related disorders.
Inversago Pharma is a private and Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
Osler, Hoskin & Harcourt LLP advised Inversago Pharma with a team consisting of included Nathalie Beauregard, Shahir Guindi , Sophie Amyot , Calvin Leung, Yulia Yugay, Vincent Legault, Marc-André Champigny, Olivier Dufrasne-Desbiens (Corporate), Alain Fournier, Jean-Philippe Dionne (Tax), and Jeremy Perron (Employment and Labour).